Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19683417 | 1.00 | GAA (0.53) | GAAALDH1A1MAPTPTGS2MAOB | |
| SCHEMBL10643494 | 0.90 | GAA (0.58) | GAAALDH1A1MAPTPTGS2MAOB | |
| SCHEMBL12201705 | 0.85 | ALDH1A1 (0.56) | GAAALDH1A1MAPTPTGS2CA1 | |
| SCHEMBL16479579 | 0.85 | ALDH1A1 (0.56) | GAAALDH1A1MAPTPTGS2CA1 | |
| SCHEMBL16479604 | 0.85 | ALDH1A1 (0.56) | GAAALDH1A1MAPTPTGS2CA1 | |
| SCHEMBL21157727 | 0.84 | GAA (0.57) | GAAALDH1A1MAPTPTGS2MAOB | |
| SCHEMBL21157751 | 0.84 | GAA (0.57) | GAAALDH1A1MAPTPTGS2MAOB | |
| SCHEMBL8605149 | 0.83 | GAA (0.56) | GAAALDH1A1MAPTPTGS2MAOB | |
| SCHEMBL3045885 | 0.83 | MAPT (0.68) | GAAALDH1A1MAPTPTGS2MAOB | |
| SCHEMBL17795378 | 0.83 | ALDH1A1 (0.57) | GAAALDH1A1MAPTPTGS2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2019-07-11 | — | — | US | disclosed |
| US-20170349621-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349621-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | GAA 1574/4885ALDH1A1 1300/4885MAPT 4213/4885 |
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | GAA 1574/4885ALDH1A1 1300/4885MAPT 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.